Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.45 |
| ▸ | SCN1A | P35498 | 5/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 5/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712133 | 0.82 | ALOX12 (0.63) | SCN9AALOX12SCN5ASCN1ASCN8A | |
| SCHEMBL15211773 | 0.74 | PKM (0.65) | SCN9AALOX12SCN5APKMMEN1 | |
| SCHEMBL16531404 | 0.72 | SCN9A (1.00) | SCN9A | |
| SCHEMBL28335404 | 0.72 | SCN1A (0.57) | SCN9ASCN5ASCN1ASCN8A | |
| SCHEMBL711858 | 0.71 | SCN9A (0.50) | SCN9ASCN5ASCN1ASCN8A | |
| SCHEMBL3806281 | 0.71 | ALOX12 (0.47) | SCN9AALOX12SCN5ASCN1ASCN8A | |
| SCHEMBL15466024 | 0.71 | MEN1 (0.40) | SCN9AALOX12SCN1AMEN1ALDH1A1 | |
| SCHEMBL29669070 | 0.71 | MEN1 (0.40) | SCN9AALOX12SCN1AMEN1ALDH1A1 | |
| SCHEMBL25090182 | 0.71 | SCN9A (0.41) | SCN9AALOX12SCN1AMEN1KMT2A | |
| SCHEMBL16784525 | 0.71 | SCN1A (0.49) | SCN1AMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2173743-A2 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012242-A2 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | SCN9A 17/4885ALOX12 1666/4885SCN5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.